 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||||||||
 |
 |
 |
|
|||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|||
 |
|
|||||||||||||||
 |
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
 |
|
||||||||
 |
|
||||||||
 |
 |
 |
|
||||||
 |
 |
 |
SOUTH SAN FRANCISCO, CA December 21, 2011 – Titan Pharmaceuticals, Inc. (OTC.BB: TTNP.OB), today announced that its board of directors has approved the adoption of a Stockholder Rights Plan and the filing of a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC) for the possible future sale of Titan securities.
Company Receives Final Meeting Minutes from the U.S. Food & Drug Administration SOUTH SAN FRANCISCO, CA December 1, 2011 – Titan Pharmaceuticals, Inc. today announced that final minutes of its Pre-New Drug Application meeting regarding Probuphine™, an innovative subcutaneous implant formulation of the marketed drug buprenorphine, have been received from the U.S. Food and Drug Administration (FDA) and confirm the previously announced regulatory path for the program SOUTH SAN FRANCISCO, CA November 15, 2011 – Titan Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Total revenues for the third quarter of 2011 were approximately $1.0 million, consisting of $973,000 in royalties on net sales of Fanapt® and $39,000 in grant revenues from the National Institutes of Health (NIH) in support of the confirmatory Phase 3 clinical study of Probuphine and the Small Business Innovation Research (SBIR) grant for Titan’s proprietary ProNeura™ drug delivery technology. SOUTH SAN FRANCISCO, CA November 15, 2011 – Titan Pharmaceuticals, Inc. today announced that it has entered into an agreement with Deerfield Management Company, L.P. and certain investment funds managed by it (Deerfield) to sell a substantial portion of the Company’s remaining future royalties on the sales of Fanapt® (iloperidone), an atypical antipsychotic approved in the U.S. for the treatment of schizophrenia in adult patients and marketed by Novartis Pharma... read more » 
|
 |
 |
 |
|
||
 |
 |
|
|||||||
Fanapt® (iloperidone)
On May 6, 2009 Fanapt, an atypical antipsychotic drug, was granted marketing approval by the US Food & Drug Administra-tion for the treatment of adult patients with schizophrenia. More... »»
Probuphine™
Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following a single treatment. This product is in Phase 3 development and has already demonstrated strong positive results... More... »» |
Titan Pharmaceuticals, Inc. is a biopharmaceutical company with valuable assets in the CNS (central nervous system) area. On May 6, 2009, US Food & Drug Administration granted marketing approval to Fanapt® (iloperi-done) for the treatment of adult patients with schizophrenia. This milestone represents the first marketing approval for a product out-licensed by Titan. The global sales from atypical antipsycho-tics, the same class of drugs like Fanapt®, exceeded $20 billion in 2007. Titan is entitled to receive 8-10% of global annual sales as royalty revenue, which may commence as early as the end of 2009. More... »» | |
|||||||